Peptide Library

AOD-9604

AOD-9604 is a synthetic peptide derived from the C-terminal fragment of human growth hormone (HGH), specifically amino acids 176–191. Unlike full-length HGH, AOD-9604 was designed to retain fat-burning properties without stimulating insulin-like growth factor 1 (IGF-1) production, which is associated with growth and metabolic side effects.

Mechanism of Action:

AOD-9604 operates by enhancing lipolysis—the breakdown of fat—while inhibiting lipogenesis, the process of creating new fat. It achieves this by stimulating beta-3 adrenergic receptors in adipocytes (fat cells), which are pivotal in fat metabolism. Notably, studies have shown that AOD-9604 can increase energy expenditure and fat oxidation, even in the absence of these receptors, suggesting alternative pathways for fat burning.

Clinical Research and Applications:

AOD-9604 has been investigated primarily for its potential in weight management and metabolic health. In animal studies, it demonstrated the ability to reduce body fat without adversely affecting insulin sensitivity. However, human clinical trials have yielded mixed results. A 12-week randomized trial indicated modest weight loss benefits, while a subsequent 24-week trial showed insufficient efficacy, leading to the termination of its development in 2007.

Safety Profile:

One of the advantages of AOD-9604 is its safety profile. Unlike full HGH, it does not stimulate IGF-1 production, thereby avoiding potential side effects such as organ growth and insulin resistance. Clinical studies have reported that AOD-9604 is well-tolerated, with minimal adverse effects.

Administration and Usage:

AOD-9604 is typically administered through subcutaneous injections or oral lozenges. The peptide is often used in conjunction with a healthy diet and exercise regimen to enhance fat loss. It's important to note that AOD-9604 is not FDA-approved for weight loss, and its use should be under medical supervision.

While AOD-9604 presents an intriguing option for targeted fat loss with a favorable safety profile, its clinical efficacy remains inconclusive. Individuals considering its use should consult healthcare professionals to weigh potential benefits and risks, especially given the lack of FDA approval for weight loss applications.

AOD-9604 dosing can vary depending on the form and the goal, but here’s a detailed breakdown based on what is commonly used in clinical and research contexts:

Typical Dosing for Fat Lose:

•Subcutaneous Injection: Most protocols suggest 250–500 mcg per day, usually administered once daily. Some advanced protocols split the dose into two injections of 250 mcg, taken in the morning and evening to potentially maximize fat metabolism.

Oral/Lozenge Form: Dosage ranges from 300–500 mcg daily, though absorption is generally lower than injections. Consistency is key with oral forms.

Cycle Duration:

Commonly used in 8–12 week cycles, followed by a 2–4 week break before restarting. This allows the body to respond without building tolerance or causing receptor downregulation.

Administration Tips:

Timing: Many users prefer taking AOD-9604 before meals to potentially enhance fat metabolism. Others take it before workouts.
Injection Sites: Subcutaneous injections are usually done in abdominal fat, thighs, or upper arm. Rotate sites to avoid irritation.
Storage: Keep reconstituted peptide in the fridge and protect from light. Use within 2–4 weeks depending on manufacturer guidance.

Important Notes:

AOD-9604 is not FDA-approved for weight loss, so all dosing recommendations are based on research studies, clinical trials, and anecdotal reports from peptide therapy practitioners.
It is generally considered safe, but consult a healthcare professional before use, especially if you have metabolic disorders, diabetes, or other health conditions.
Combining with diet and exercise significantly improves outcomes; AOD-9604 alone is unlikely to produce dramatic fat loss.

AOD-9604 Injectable Protocol:

•Goal: Fat loss / metabolism support
Form: Subcutaneous injection

•Time of day dose- Morning (fasted) use 50 mcg. Inject subcutaneously in the abdominal area or thigh. Fasting may enhance fat metabolism.

•Evening does (optional) Use 250 mcg. Only if splitting dose can be before dinner or pre-workout in the evening.

Cycle:

8–12 weeks continuous use.
2–4 week break between cycles.

Administration Tips:

Rotate injection sites to prevent irritation.
Reconstituted peptide should be stored in the fridge, away from light, and used within 2–4 weeks.
Inject at a 45-degree angle into subcutaneous fat.

AOD-9604 Oral/Lozenge Protocol:

Goal: Fat loss / metabolism support
Form: Oral lozenge or sublingual

Time of Day dose -Morning

300–500 mcg.

Take before breakfast; hold under the tongue until fully dissolved for better absorption.

Pre-workout (optional) 250–300 mcg. May enhance fat oxidation during exercise.

Cycle:

8–12 weeks continuous use
2–4 week break before next cycle

Administration Tips:

Consistency is important; take at roughly the same times daily.
Combine with regular exercise and a balanced diet to maximize fat loss.

Additional Tips:

Hydration: Keep hydrated to support metabolism.
Diet: A moderate calorie deficit plus protein intake can improve results.
Monitoring: Track body composition rather than just weight for better results.
Stacking: Some protocols combine AOD-9604 with other peptides like CJC-1295 without DAC for enhanced growth hormone pulse support, but do this only under medical supervision.

BPC-157 oral and injectable

BPC-157, or Body Protection Compound-157, is a synthetic peptide derived from a naturally occurring protein in the stomach. It’s primarily researched for its regenerative and healing properties, especially in tendon, ligament, muscle, and gut repair. BPC-157 is known for promoting angiogenesis (formation of new blood vessels), reducing inflammation, and accelerating tissue recovery.

Injectable BPC-157

Form and Administration:

Typically supplied as a lyophilized (freeze-dried) powder.
Reconstituted with bacteriostatic water before use.
Administered subcutaneously (under the skin) or intramuscularly (directly into the tissue near injury).

Dosage Protocols:

Subcutaneous: 250–500 mcg daily, often split into two injections near the injury site.
Intramuscular: Similar dosing; more targeted to specific muscles, tendons, or ligaments.

Advantages:

Direct delivery to the bloodstream or local tissue results in higher bioavailability and faster action.
Often considered more reliable for tissue healing than oral forms.
Can be targeted near the site of injury for localized repair.

Considerations:

Requires careful preparation and sterile technique.
Slight discomfort at the injection site.
Effects are typically reported within days to a couple of weeks, depending on injury severity.

Oral BPC-157

Form and Administration:

Comes as capsules, sublingual tablets, or liquid solutions.
Taken orally or sublingually, sometimes mixed in water for sublingual absorption.

Dosage Protocols:

Typical doses range from 200–500 mcg per day.
Sublingual administration may slightly increase bioavailability compared to standard oral ingestion.

Advantages:

Non-invasive and convenient.
Lower risk of infection or improper administration.
Suitable for systemic healing, including gut repair, due to its oral bioavailability.

Considerations:

Oral BPC-157 is less studied than injectable forms; absorption can vary.
Effects may take longer to manifest compared to targeted injections.
Dosing consistency and gastrointestinal degradation can impact effectiveness.

Effects and Benefits (both forms):

Accelerates healing of tendons, ligaments, muscles, and skin.
Reduces inflammation and protects tissues from further damage.
Promotes angiogenesis for faster tissue repair.
May aid gut lining repair, potentially helping with ulcers or inflammatory gut conditions.

Injectable BPC-157

Form: Lyophilized powder reconstituted with bacteriostatic water.

Typical Doses:

Subcutaneous (under the skin): 250–500 mcg per day, often split into 2 injections.
Intramuscular (into the muscle near injury): 250–500 mcg per day.
Duration: Usually 2–4 weeks for tissue repair, sometimes longer for chronic injuries.

Tips:

For localized injuries, inject as close as possible to the affected tissue.
Daily dosing is common; some protocols divide the total daily dose into morning and evening injections.
Always use sterile technique to prevent infection.

Oral BPC-157

Form: Capsules, sublingual tablets, or liquid solutions.

Typical Doses:

200–500 mcg per day, sometimes split into 2 doses (morning and evening).
Sublingual administration may improve absorption.
Duration mirrors injectable protocols, typically 2–4 weeks for injury repair.

Tips:

Take on an empty stomach to improve absorption.
Oral is preferred for systemic issues (like gut healing) rather than localized injuries.

Combination Protocol (Optional)

Some users combine oral and injectable forms for more comprehensive healing:

Inject 250 mcg near the injury site daily.
Take 200–300 mcg orally for systemic support, especially for gut or general tissue repair.

Week 1–4: Combined BPC-157 (Subcutaneous/Intramuscular)

Dose: 250 mcg daily
Timing: Morning (or split morning/evening: 125 mcg each)

Administration:

Subcutaneous: Inject near the injury site
Intramuscular: Inject into the muscle closest to the affected tissue.
Notes: Use sterile technique; rotate injection sites if needed.
Oral (Capsule or Sublingual)
Dose: 200–300 mcg daily
Timing: Morning and evening (split dose 100–150 mcg each)

Administration:

Take on an empty stomach for best absorption.
Sublingual form may improve bioavailability.

Additional Guidelines

Duration: 2–4 weeks, depending on injury severity.
Storage: Keep reconstituted injectable refrigerated; oral forms per label.
Observation: Monitor healing progress and adjust doses only if necessary.
Safety: Avoid injections into veins; maintain sterile technique; discontinue if irritation or unusual reactions occur.

Delta Sleep-Inducing Peptide (DSIP)

Primary Functions

Sleep Regulation:
DSIP is most well-known for its ability to influence sleep patterns, particularly slow-wave sleep (deep, restorative sleep). It does not appear to act like conventional sedatives; instead, it seems to modulate the body’s natural sleep-wake cycles by affecting neurotransmitter systems and possibly the hypothalamic-pituitary-adrenal (HPA) axis.
Stress Modulation:
DSIP may help regulate the stress response by influencing cortisol levels. Some studies suggest it can reduce elevated cortisol, potentially contributing to relaxation and improved sleep quality in individuals experiencing stress-related sleep disturbances.
Pain and Analgesic Effects:
Research indicates DSIP might have mild analgesic (pain-relieving) properties. It seems to interact with the body’s pain pathways, possibly by influencing endorphin release, though evidence is limited.
Endocrine Influence:
DSIP has been linked to modulation of the endocrine system. There is some evidence that it can influence growth hormone release and possibly interact with the reproductive hormone axis, though these effects are less understood and inconsistent across studies.
Neuroprotective and Mood Effects:
Preliminary animal studies suggest DSIP may have neuroprotective properties and could influence mood and anxiety, but human data are sparse.

Mechanism of Action:

DSIP’s exact mechanism is not fully understood. It appears to interact with multiple neurotransmitter systems, including GABA, serotonin, and melatonin pathways, which play key roles in sleep regulation. It may also affect the HPA axis, balancing stress hormones and stabilizing sleep patterns.

Administration and Research:

DSIP is typically studied in research settings, often administered intravenously or via intranasal routes in animals. Oral bioavailability is very low due to peptide degradation in the digestive tract. There is limited clinical data in humans, so usage is largely experimental or investigational.

Potential Uses:

Improving sleep quality, particularly deep slow-wave sleep
Reducing stress-induced sleep disturbances
Supporting mild pain management or mood regulation (experimental)

Safety and Considerations:

DSIP is generally considered low in toxicity in research models
Effects in humans are not well-documented
Long-term safety and optimal dosing are not established

DSIP is a sleep-modulating peptide with additional potential roles in stress regulation, pain modulation, and neuroprotection. Its research is still early, particularly in humans, but it remains a peptide of interest for sleep disorders and related conditions.

Delta Sleep-Inducing Peptide (DSIP) dosing is not well-established because human clinical research is very limited. Most dosing information comes from animal studies or anecdotal biohacker reports.

Typical Experimental Dosing:(Human/Research Context)

Intravenous (IV) or Subcutaneous (SC) Injection:
Studies in humans and anecdotal reports suggest doses around 100–300 micrograms per day. Some protocols split the dose into multiple smaller injections.
Timing:
Because DSIP primarily affects slow-wave sleep, it’s usually administered 30–60 minutes before bedtime.

Other Considerations:

Oral administration is ineffective, as the peptide is broken down in the digestive system.
Short half-life: DSIP has a short half-life in the bloodstream, often only 10–15 minutes, so timing relative to sleep is important.
Stacking: Some biohackers combine DSIP with melatonin, GABA, or other sleep-promoting peptides to enhance deep sleep effects, though this is experimental.

Safety Notes:

Human data are sparse; start at the lower end of reported doses if experimenting in a research context.
Long-term safety is unknown.
Avoid concurrent use with sedatives unless under clinical supervision.

DSIP Sleep Stack Protocol:

1. Core Peptide: DSIP

Dose: 100–200 mcg
Route: Subcutaneous (SC) injection is preferred; intravenous (IV) is also used in research settings
Timing: 30–60 minutes before bedtime
Frequency: Once daily, typically in the evening
Notes: Start at the lower end (100 mcg) to gauge response. DSIP has a short half-life (~10–15 minutes), so timing relative to sleep onset is critical.

2. Sleep Synergy Compounds:

Melatonin

Dose: 0.5–3 mg
Timing: 30–60 minutes before bedtime
Purpose: Enhances sleep onset; can complement DSIP’s effect on deep sleep

GABA (Gamma-Aminobutyric Acid)

Dose: 250–500 mg
Timing: 30 minutes before bed
Purpose: Supports relaxation and slows nervous system activity; may enhance DSIP’s sleep-promoting effects

Magnesium (Glycinate or Threonate)

Dose: 200–400 mg
Timing: Evening with food or 30 minutes before bed
Purpose: Supports muscle relaxation, nervous system calm, and sleep quality

Optional Stack Enhancers:

5-HTP (Serotonin Precursor)

Dose: 50–100 mg
Timing: 30–60 minutes before bed
Purpose: Supports serotonin and melatonin production; may improve sleep depth

Cognitive/Recovery Support:

Some biohackers add MOTS-C or GH secretagogues earlier in the evening to support recovery and hormonal balance, though these are optional and highly experimental

4. Suggested Protocol Example:

7:00–8:00 PM – Light dinner, avoid caffeine
9:30 PM – Take magnesium + optional 5-HTP
10:00 PM – Subcutaneous DSIP injection + melatonin + GABA
10:30–11:00 PM – Lights out; ensure dark, quiet environment

5. Safety Notes:

Monitor for excessive drowsiness or unusual reactions
Avoid combining with prescription sedatives without medical guidance
Long-term human safety data are limited; use the lowest effective dose

Delta Sleep-Inducing Peptide (DSIP) is a naturally occurring neuropeptide that was first discovered in the 1970s in the brains of rabbits. It is a short peptide consisting of nine amino acids (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) and is primarily associated with regulating sleep, though research has suggested it may have additional physiological effects. Here’s a detailed breakdown:

Primary Functions:

Sleep Regulation
DSIP is most well-known for its ability to influence sleep patterns, particularly slow-wave sleep (deep, restorative sleep). It does not appear to act like conventional sedatives; instead, it seems to modulate the body’s natural sleep-wake cycles by affecting neurotransmitter systems and possibly the hypothalamic-pituitary-adrenal (HPA) axis.
Stress Modulation:
DSIP may help regulate the stress response by influencing cortisol levels. Some studies suggest it can reduce elevated cortisol, potentially contributing to relaxation and improved sleep quality in individuals experiencing stress-related sleep disturbances.
Pain and Analgesic Effects:
Research indicates DSIP might have mild analgesic (pain-relieving) properties. It seems to interact with the body’s pain pathways, possibly by influencing endorphin release, though evidence is limited.
Endocrine Influence:
DSIP has been linked to modulation of the endocrine system. There is some evidence that it can influence growth hormone release and possibly interact with the reproductive hormone axis, though these effects are less understood and inconsistent across studies.
Neuroprotective and Mood Effects:
Preliminary animal studies suggest DSIP may have neuroprotective properties and could influence mood and anxiety, but human data are sparse.

Mechanism of Action:

Administration and Research:
DSIP is typically studied in research settings, often administered intravenously or via intranasal routes in animals. Oral bioavailability is very low due to peptide degradation in the digestive tract. There is limited clinical data in humans, so usage is largely experimental or investigational.

Potential Uses:

Improving sleep quality, particularly deep slow-wave sleep
Reducing stress-induced sleep disturbances
Supporting mild pain management or mood regulation (experimental)

Safety and Considerations:

DSIP is generally considered low in toxicity in research models
Effects in humans are not well-documented
Long-term safety and optimal dosing are not established

In short, DSIP is a sleep-modulating peptide with additional potential roles in stress regulation, pain modulation, and neuroprotection. Its research is still early, particularly in humans, but it remains a peptide of interest for sleep disorders and related conditions.

Delta Sleep-Inducing Peptide (DSIP) dosing is not well-established because human clinical research is very limited. Most dosing information comes from animal studies or anecdotal biohacker reports. Here’s a careful overview:

Typical Experimental Dosing:(Human/Research Context)

Intravenous (IV) or Subcutaneous (SC) Injection:
Studies in humans and anecdotal reports suggest doses around 100–300 micrograms per day. Some protocols split the dose into multiple smaller injections.

Timing:
Because DSIP primarily affects slow-wave sleep, it’s usually administered 30–60 minutes before bedtime.

Other Considerations:

Oral administration is ineffective, as the peptide is broken down in the digestive system.
Short half-life: DSIP has a short half-life in the bloodstream, often only 10–15 minutes, so timing relative to sleep is important.
Stacking: Some biohackers combine DSIP with melatonin, GABA, or other sleep-promoting peptides to enhance deep sleep effects, though this is experimental.

Safety Notes:

Human data are sparse; start at the lower end of reported doses if experimenting in a research context.
Long-term safety is unknown.
Avoid concurrent use with sedatives unless under clinical supervision.

Ipamorelin

Ipamorelin is a synthetic peptide that belongs to the class of growth hormone-releasing peptides (GHRPs). It is primarily used to stimulate the body’s natural production of growth hormone (GH) in a controlled and selective manner. Compared to other GHRPs like GHRP-6 or GHRP-2, Ipamorelin is considered more targeted and has a cleaner side-effect profile.

Mechanism of Action:
Ipamorelin works by binding to the ghrelin receptor (also known as the growth hormone secretagogue receptor) in the pituitary gland. This binding stimulates the secretion of growth hormone without significantly affecting other hormones like cortisol, prolactin, or aldosterone. Because of its selectivity, it produces fewer unwanted hormonal side effects compared to older GHRPs.

Benefits:

Muscle Growth and Recovery: By increasing GH levels, Ipamorelin supports muscle protein synthesis, which can enhance muscle growth, strength, and recovery after workouts.
Fat Loss: Elevated GH promotes lipolysis, which helps the body break down fat for energy, particularly visceral fat.
Anti-Aging Effects: Growth hormone has effects on skin elasticity, hydration, and overall tissue repair, so Ipamorelin can contribute to healthier, more youthful-looking skin.
Bone Health: GH stimulates the production of insulin-like growth factor-1 (IGF-1), which supports bone density and overall skeletal strength.
Sleep Improvement: Some users report improved sleep quality, likely due to the GH release patterns stimulated by Ipamorelin.

Dosage and Administration:
Ipamorelin is typically administered via subcutaneous or intramuscular injection. Dosing protocols vary, but common regimens include daily injections, often split into morning and evening doses to mimic natural GH rhythms. It is frequently used in combination with other peptides like CJC-1295 (a growth hormone-releasing hormone analog) for synergistic effects.

Side Effects:
Ipamorelin is generally well-tolerated. Because it is selective for GH release, it produces minimal increases in cortisol or prolactin. Potential side effects are usually mild and may include:

Temporary water retention
Headaches
Mild dizziness
Injection site irritation

It is considered one of the safer GHRPs, particularly for long-term use in anti-aging or muscle-building protocols.

Summary:
Ipamorelin is a precise, selective growth hormone secretagogue that encourages the body to produce more GH naturally. Its benefits include muscle growth, fat loss, anti-aging effects, bone health support, and improved sleep, with a lower risk of hormonal side effects than many other peptides. It is often chosen by individuals seeking a safe and effective way to elevate GH levels without significant disruptions to other endocrine functions.

Ipamorelin dosing depends on your goals, anti-aging, muscle growth, fat loss, or a combination and whether it’s used alone or stacked with another peptide like CJC-1295.

Typical Dosing Protocols:

Anti-Aging / General Wellness

Dose: 100–200 mcg per injection
Frequency: 1–2 times per day
Timing: Morning (fasted) or before bed; the evening dose can enhance natural GH pulse during sleep.

Muscle Growth / Fat Loss:
- Dose: 200–300 mcg per injection
- Frequency: 2–3 times per day
- Timing:
  - Pre-workout to support GH spike and recovery
  - Before meals or fasted periods to support fat metabolism
  - Before sleep for maximal GH release

Stacking with CJC-1295 (with DAC or without DAC):
- Ipamorelin Dose: 100–200 mcg per injection
- CJC-1295 Dose: 100 mcg per injection
- Frequency: Typically 1–2 times daily
- Timing: Split doses can mimic natural GH pulsatility—morning and evening

Injection Tips:

Administer subcutaneously (under the skin) for best absorption.
Rotate injection sites to minimize irritation.
Use a fresh syringe for each injection to maintain sterility.

Cycle Duration:

Common cycles last 8–12 weeks, followed by a break to assess results and reduce the risk of receptor desensitization.

Notes:

Doses can be adjusted based on age, GH response, and goals.
Ipamorelin is mild compared to other GHRPs, so overdosing is less risky, but very high doses can still cause water retention or headaches.

Sermorelin

Sermorelin acetate is a synthetic peptide consisting of 29 amino acids, and it functions as a growth hormone-releasing hormone (GHRH) analog. Essentially, it stimulates the pituitary gland to produce and release more human growth hormone (HGH) naturally, rather than supplying HGH directly. Because of this indirect approach, it tends to have a lower risk of side effects compared with direct HGH therapy.

Mechanism of Action:
Sermorelin binds to specific receptors on the pituitary gland, triggering the natural release of HGH. This results in increased production of insulin-like growth factor 1 (IGF-1) in the liver, which mediates many of the anabolic and regenerative effects of HGH. By using Sermorelin, the body maintains a more physiological rhythm of hormone release, which reduces the risk of overexposure compared with direct HGH injections.

Uses and Benefits:

Anti-Aging: Can improve skin elasticity, reduce wrinkles, and increase energy levels.
Body Composition: Helps increase lean muscle mass and reduce body fat, particularly when combined with proper diet and exercise.
Recovery: Supports tissue repair and recovery, making it appealing to athletes and those with injuries.
Sleep Quality: Can enhance deep sleep, which is crucial for overall regeneration.
Bone Density: May help improve bone mineral density over time.

Administration:
Sermorelin is typically administered via subcutaneous injection, often in the evening to mimic the body’s natural HGH secretion pattern. Oral administration is not effective because the peptide would be broken down in the digestive tract. Standard dosing varies, but common protocols involve daily injections of around 0.2 to 0.3 mg, adjusted based on individual response, IGF-1 levels, and goals.

Side Effects:
Sermorelin is generally well-tolerated. Possible mild side effects include:

Injection site irritation or redness
Headaches
Flushing
Dizziness
Temporary tingling or numbness

Serious side effects are rare because it encourages natural HGH production rather than flooding the body with exogenous hormone.

Comparison to HGH Therapy:

Safety: Lower risk of acromegaly, insulin resistance, and fluid retention.
Cost: Generally less expensive than full HGH therapy.
Effectiveness: Slower and subtler effects since it relies on the pituitary’s capacity to produce HGH.

Summary:
Sermorelin is a bio-identical GHRH analog designed to gently stimulate the body’s natural growth hormone production. Its main appeal is anti-aging, improved body composition, and recovery benefits, all with a relatively low risk of side effects compared to direct HGH therapy.

Sermorelin dosing:

Typical Administration:

Route: Subcutaneous injection (just under the skin, usually in the belly or thigh). Oral forms are ineffective because the peptide is broken down in the digestive tract.
Frequency: Usually once daily, often at night to align with the body’s natural growth hormone pulse during deep sleep. Some protocols use 5–7 times per week.

Standard Dose Range:

Adults: 0.2 to 0.3 mg per day is typical for anti-aging purposes.
Higher doses: Sometimes 0.3–0.5 mg per day is used under medical supervision for specific goals like muscle growth or recovery.

Timing Considerations:

Administer 30–60 minutes before bedtime for best results.
Avoid dosing immediately after meals, especially those high in carbohydrates, because insulin spikes can blunt HGH release.

Cycle Length:

Sermorelin is usually taken continuously, not in cycles, because it stimulates natural HGH production gradually. A typical course is 3–6 months before evaluating progress and IGF-1 levels.

Monitoring:

IGF-1 blood levels are commonly checked every few months to ensure effectiveness and adjust dosing.
Dose adjustments are based on IGF-1 response, age, and individual goals.

Notes:

Start at the lower end of the dosing range and increase only if necessary and under supervision.
Combining Sermorelin with other peptides like CJC-1295 can enhance HGH release, but this requires careful dosing to avoid overstimulation.

Daily Dose: 0.2 mg subcutaneous injection
Timing: 30–60 minutes before bedtime

Additional Notes:

Injection Sites: Rotate between abdomen and thighs to reduce irritation.
Meal Timing: Ideally, wait 1–2 hours after your last meal before injecting. Avoid immediately following high-carb meals.
Monitoring: Check IGF-1 every 8–12 weeks to track response and adjust dose if needed.
Adjustments: Some users increase to 0.25–0.3 mg per day if IGF-1 remains low or for more pronounced body composition goals, but only under supervision.

MOTS-C

MOTS‑C is a naturally occurring mitochondrial-derived peptide composed of 16 amino acids. It was first identified in 2015 as part of a growing class of small peptides encoded by mitochondrial DNA, rather than nuclear DNA, and has been studied for its role in metabolism, energy regulation, and aging.

Structure and Origin:

MOTS‑C is encoded by a short open reading frame within the 12S ribosomal RNA gene of mitochondrial DNA.
Its sequence is 16 amino acids long, making it relatively small compared to most proteins, but large enough to have specific biological effects.

Mechanism of Action:

MOTS-C interacts with cellular metabolism, particularly in skeletal muscle and liver cells.
It activates the AMPK pathway (adenosine monophosphate–activated protein kinase), which is a key regulator of energy balance and metabolic homeostasis.
By influencing AMPK, MOTS-C can improve glucose uptake in muscle cells, enhance insulin sensitivity, and regulate lipid metabolism.
It also plays a role in inhibiting the folate-methionine cycle, which can influence cellular stress responses and longevity pathways.

Physiological Effects:

Metabolic Health: MOTS-C has been shown to help lower blood glucose levels and improve insulin sensitivity in animal studies. This makes it a potential target for metabolic disorders like type 2 diabetes.
Fatigue and Energy Regulation: By improving cellular energy metabolism, MOTS-C can enhance exercise capacity and reduce fatigue in animal models.
Anti-Aging Potential: MOTS-C may support healthy aging by promoting mitochondrial function, improving metabolic flexibility, and regulating pathways linked to age-related diseases.
Weight Management: In studies with mice, MOTS-C prevented diet-induced obesity and improved overall metabolic health.

Therapeutic Potential:

Research is still largely preclinical, but MOTS-C has attracted interest as a candidate for therapies targeting metabolic syndrome, diabetes, obesity, and age-related metabolic decline.
Its effects on cellular stress responses also suggest potential in supporting resilience against mitochondrial dysfunction, which is implicated in various chronic diseases.

Pharmacokinetics and Administration:

MOTS-C is typically studied as an injectable peptide in research settings.
Its half-life in circulation is relatively short, necessitating careful dosing considerations in experimental or therapeutic contexts.
Oral bioavailability is very low due to degradation in the gastrointestinal tract.

In summary, MOTS-C is a small but highly influential peptide that bridges mitochondrial function and systemic metabolism, showing promise in managing metabolic disorders and supporting longevity pathways. Its research is still in the early stages, but findings so far suggest it could be a key player in the future of metabolic and anti-aging therapies.

MOTS-C dosing is still largely experimental, as it has not been approved for human therapeutic use. Most available information comes from animal studies and very limited early human research.

1. Animal Studies (Most Common Reference):

Mice are often dosed with MOTS-C at 5–15 mg/kg per day, usually via subcutaneous injection.
Effects observed include improved insulin sensitivity, reduced fat accumulation, and enhanced exercise performance.

2. Human Research (Limited):

Very few human studies exist, and dosing protocols are not standardized.
Some early trials or experimental reports suggest low microgram to milligram ranges per kg body weight, delivered via injection. Exact dosing schedules vary depending on study design.

3. Administration Considerations:

MOTS-C is peptide-based, so it is generally injected subcutaneously rather than taken orally, because it would be broken down in the digestive system.
Frequency in animal studies is usually once or twice daily, depending on the protocol.
There’s no established oral formulation with reliable bioavailability.

4. Safety Notes:

Long-term safety in humans is unknown.
Most information comes from short-term studies in animals.
Dosing in humans should be approached cautiously and only under controlled research settings.

Semax and Selank

Semax

Type: Peptide / Nootropic / Neuroprotective
Structure: Synthetic heptapeptide (sequence: Met-Glu-His-Phe-Pro-Gly-Pro)
Primary Uses: Cognitive enhancement, neuroprotection, mood regulation

Mechanism of Action:

Semax is derived from adrenocorticotropic hormone (ACTH) fragments, but it does not have hormonal activity like ACTH.
It primarily influences the brain by modulating brain-derived neurotrophic factor (BDNF), which supports neuron growth, survival, and plasticity.
It also affects monoamine neurotransmitters (dopamine, serotonin, norepinephrine), helping improve focus, learning, and mood regulation.
Some studies suggest it may reduce oxidative stress and improve cerebral blood flow.

Effects and Benefits:

Enhanced memory, learning capacity, and attention span.
Improved mental clarity and cognitive resilience under stress.
Mild neuroprotective effects against ischemia and neurodegenerative processes.
Potential mood stabilization and anti-anxiety effects.

Administration:

Typically administered nasally for quick absorption; subcutaneous injection is also used in research settings.
Dosing varies based on intended effect, often in microgram (µg) ranges per day.

Safety:

Generally considered safe with minimal side effects when used at recommended doses.
Side effects are rare but may include mild nasal irritation or transient headaches.

Selank

Type: Peptide / Nootropic / Anxiolytic
Structure: Synthetic heptapeptide (sequence: Thr-Lys-Pro-Arg-Pro-Gly-Pro)
Primary Uses: Anxiety reduction, cognitive support, immune modulation.

Mechanism of Action:

Selank is modeled after endogenous tetrapeptides with regulatory functions in the nervous system.
It modulates GABAergic systems, promoting calm and reducing anxiety without sedation.
It also affects serotonin and dopamine systems, contributing to mood stabilization.
Evidence suggests it can increase BDNF levels and support cognitive function.
It has mild immunomodulatory properties, potentially supporting antiviral responses.

Effects and Benefits:

Reduces anxiety and stress without causing drowsiness.
Enhances memory, attention, and learning.
Supports mental resilience under stressful conditions.
May have protective effects on neurons and improve recovery after cognitive strain.

Administration:

Most commonly nasally, allowing direct access to the central nervous system.
Typical doses are also in the microgram range, with dosing frequency depending on the desired effect.

Safety:

Well-tolerated in research studies; side effects are minimal.
May cause slight nasal irritation in some users.

Summary:

Both Semax and Selank are synthetic peptides with cognitive and neuroprotective properties, primarily administered nasally.
Semax focuses more on cognition, memory, and neuroprotection, while Selank is better known for anxiolytic effects and stress resilience.
Many users combine them for synergistic effects, but careful dosing and research-backed protocols are recommended.

Semax/Selank Dosing

Common Methods: Nasal spray (most popular), subcutaneous injection (less common)

Typical Nasal Dose (for cognitive enhancement):

Low dose: 200–600 mcg per day, divided into 2–3 doses.

TB-500 oral and subq

What TB-500 Is

TB-500 is a synthetic version of thymosin beta-4, a naturally occurring peptide present in almost all human and animal cells. It plays a key role in cell migration, tissue regeneration, and wound healing. Unlike other peptides that target hormone pathways, TB-500 primarily works on cellular repair and anti-inflammatory processes, making it popular for tissue recovery, joint healing, and tendon repair.

Mechanism of Action

Promotes actin filament formation: TB-500 helps cells move and repair damaged tissue by increasing actin availability.
Reduces inflammation: It can modulate inflammatory signals in injured tissues.
Enhances angiogenesis: TB-500 may stimulate new blood vessel growth, which supports healing.
Accelerates tissue repair: Particularly effective for tendons, ligaments, skin, and muscles.

Forms and Administration

1. Subcutaneous (SubQ) Injection

Absorption: Directly enters the subcutaneous tissue, allowing for efficient systemic distribution.
Typical dosing: Commonly 2–5 mg per week, divided into 2–3 injections. Healing protocols sometimes start with higher “loading” doses for the first 4–6 weeks.

Advantages:

Higher bioavailability than oral forms.
More predictable blood levels.
Faster tissue uptake.

Administration tips:

Inject into fatty tissue just under the skin (commonly abdomen or thigh).
Rotate injection sites to avoid irritation.
TB-500 is often reconstituted with bacteriostatic water and stored refrigerated.

Onset of effect: Initial tissue repair benefits may appear within 1–2 weeks, though complete regenerative effects can take several weeks.

2. Oral Administration

Absorption challenges: TB-500, being a peptide, is prone to degradation in the digestive tract, so oral bioavailability is extremely low.

Delivery methods: Some formulations are marketed as sublingual or enteric-coated capsules to bypass stomach acid.

Effectiveness:
Oral TB-500 is significantly less potent than injectable forms.
Many users report minimal results from oral use unless high doses or advanced delivery systems are used.

Advantages:

Non-invasive, easier to administer.
Reduced risk of injection site complications.

Disadvantages:

Poor absorption and variable effects.
Often much more expensive per milligram due to lower efficacy.

Safety and Side Effects:

TB-500 is generally considered low-risk when used at reasonable doses.
Reported side effects are mild and may include:
Temporary fatigue or drowsiness.
Slight redness or irritation at injection site.
Rare headaches or dizziness.
There’s limited human clinical data, so long-term safety is not fully established.

Summary

SubQ injection is the most effective route for TB-500 due to better absorption and predictable tissue targeting.
Oral forms exist but are far less reliable because peptides are broken down in the digestive system.
TB-500 is mainly used for healing, tissue repair, and anti-inflammatory benefits, rather than muscle growth or fat loss.

1. Subcutaneous (SubQ) Dosing Protocols:

a. Loading Phase

Purpose: Quickly raise tissue levels to jumpstart healing.
Typical dose: 2–5 mg per week, split into 2–3 injections.
Example schedule:
2 mg every other day for 2–4 weeks (total 6–12 mg in the loading phase).
Notes: Some protocols go up to 5 mg per week if addressing more severe injuries, but higher doses should be monitored carefully.

b. Maintenance Phase

Purpose: Maintain elevated tissue levels for ongoing healing.
Typical dose: 2 mg once weekly or 2 mg every 3–4 days.
Duration: 4–6 weeks is common, though longer-term use is sometimes reported for chronic injuries.
Notes: Maintenance dosing is usually lower than the loading phase and may continue until recovery is complete.

2. Administration Tips

Inject into fatty tissue, such as the abdomen or thigh, away from the umbilicus.
Rotate injection sites to avoid irritation.
Reconstitute with bacteriostatic water and store in the refrigerator.
TB-500 is stable for several weeks once reconstituted if kept cold.

3. Oral TB-500

No standard dosing exists due to poor absorption.
Users often need much higher doses or specialized delivery systems, but effectiveness is unpredictable.
Injectable routes are recommended for consistent results.

4. Safety Notes

Mild side effects may include fatigue, temporary headache, or minor injection site irritation.
Avoid very high doses without professional supervision, as long-term effects are not well-studied.

TB-500 dosing schedule table for subcutaneous use:

Dose per Injection 2 mg

Every other day

2–4 weeks

Purpose: Quickly raise tissue levels. Some protocols use up to 5 mg/week if injury is severe.

Maintenance dose 2 mg

1–2 times per week

4–6 weeks

Purpose: Maintain elevated tissue levels. Can extend until healing is complete.

Extended Use-2 mg

Every 3–4 days

Optional

For chronic injuries or long-term tissue repair. Monitor for side effects.

Administration Tips:

Inject into fatty tissue (abdomen, thigh).
Rotate injection sites to prevent irritation.
Reconstitute with bacteriostatic water and store refrigerated.
Observe for mild side effects: fatigue, headaches, minor injection site redness.

Key Points:

Oral TB-500 is generally unreliable due to poor absorption.
Most users achieve best results with subcutaneous injections.
Adjustments may be made depending on injury severity and individual response.

GHK-Cu

GHK-Cu, also called Copper Peptide GHK-Cu, is a small, naturally occurring tripeptide composed of three amino acids: glycine, histidine, and lysine, bound to a copper ion. It is most notable for its wound healing, anti-aging, and regenerative properties. Here's a detailed breakdown:

Structure and Function

Molecular structure: Glycyl-L-histidyl-L-lysine-Cu²⁺. The copper ion is essential for its biological activity.
Natural occurrence: Found in plasma, saliva, and urine. Its levels tend to decline with age, which is thought to contribute to slower tissue repair and aging skin.

Mechanism of Action

GHK-Cu influences multiple cellular pathways:

Tissue Repair: It promotes the synthesis of collagen, elastin, and glycosaminoglycans, which are crucial for skin elasticity, firmness, and healing.
Anti-inflammatory: Modulates inflammation, reducing excessive inflammatory responses in damaged tissue.
Angiogenesis: Stimulates the formation of new blood vessels, improving nutrient delivery and tissue regeneration.
Antioxidant effects: Reduces oxidative stress and helps protect cells from free radical damage.
Gene regulation: Can activate and suppress specific genes related to tissue repair, inflammation, and aging. Research shows it can influence over 4,000 human genes, including those involved in wound healing, cell proliferation, and DNA repair.

Clinical and Cosmetic Applications

Skin and aesthetics: Commonly used in anti-aging creams and serums to reduce fine lines, wrinkles, sagging skin, and hyperpigmentation.
Hair regrowth: Studies indicate it can stimulate hair follicle growth, potentially helping with androgenic alopecia.
Wound healing: Topical or injectable forms accelerate healing of ulcers, burns, and post-surgical wounds.
Medical research: Investigated for lung repair, liver regeneration, and anti-cancer potential due to its cellular repair effects.

Forms and Administration

Topical creams and serums: Most common for cosmetic use, generally 0.1–0.5% concentration.
Injectables: Used in research or clinical settings for wound healing or tissue regeneration.
Stability: Sensitive to light and oxidation; often formulated with stabilizers to preserve activity.

Safety Profile

Generally well-tolerated with minimal adverse effects when used topically.
Rarely, mild irritation or redness may occur.
Long-term systemic effects are still under investigation, though naturally occurring levels in humans suggest low toxicity.

In summary, GHK-Cu is a versatile peptide with strong evidence for skin rejuvenation, tissue repair, and anti-inflammatory benefits, making it one of the most widely studied and applied peptides in cosmetic and regenerative medicine.

Dosing GHK-Cu depends on the formulation and purpose—topical, injectable, or research use—but here’s a practical breakdown based on current research and cosmetic use:

1. Topical Use (Skin, Hair, Anti-Aging)

Concentration: 0.1% to 0.5% GHK-Cu is standard in creams or serums.
Application: Apply once or twice daily to clean skin. Focus on areas with wrinkles, sagging, or hair thinning.
Duration: Visible results can take 4–12 weeks depending on skin condition and formulation.
Note: Peptide stability is sensitive to light and air, so store products in dark, airtight containers.

2. Injectable Use (Wound Healing, Research, Tissue Regeneration)

Typical concentration: 2–5 mg per mL, depending on the intended tissue site.
Volume: Small localized injections, often 0.5–1 mL per site.
Frequency: Every 1–3 days in clinical research; some protocols use weekly injections for skin rejuvenation.
Note: Injectable use should be overseen by a healthcare professional experienced with peptide therapy.

3. Hair Regrowth

Topical sprays or microneedling solutions use 0.2–0.5% GHK-Cu.
Applied 2–3 times per week to the scalp; studies suggest improved follicle activity over several months.

Key Safety Points

Avoid high systemic doses; topical or localized use is safest.
Mild irritation can occur with topical use.
Combine with other peptides like Matrixyl or Copper Tripeptide complexes for synergistic anti-aging effects.
Do not mix directly with harsh acids or vitamin C in the same formulation; it can destabilize the peptide.

Usage Tips
Topical layering: Apply GHK-Cu first, allow 5–10 minutes absorption, then layer other peptides or moisturizers.
Scalp application: Use GHK-Cu + copper tripeptide 2–3 times per week; microneedling can increase absorption.
Injectable use: Only under clinical supervision; combining GH secretagogues like CJC-1295 or Ipamorelin can amplify tissue regeneration.
Cycle duration: For skin, 8–12 weeks per intensive cycle; for hair, 3–6 months. After this, reduce frequency for maintenance.
Storage: Keep all peptide serums in dark, airtight containers; avoid direct sunlight or high heat.

What is the best peptide for muscle growth?

For muscle growth, the peptide that consistently stands out is IGF-1 LR3 (Insulin-like Growth Factor 1, Long Arg3 variant). It directly promotes muscle cell proliferation and differentiation, essentially telling muscle tissue to grow and repair more effectively.

Here are the main contenders often discussed for muscle-building purposes:

1. IGF-1 LR3

Potent at stimulating new muscle cell growth (hyperplasia) and increasing protein synthesis.
Works downstream of growth hormone, so it provides more direct anabolic effects.

2. CJC-1295 (with DAC) or CJC-1295 + Ipamorelin

Stimulates your body’s natural release of growth hormone.
Increases IGF-1 levels indirectly, which supports lean mass gains, recovery, and fat loss.
Better for a longer-term, steady boost rather than rapid muscle increase.

3. Follistatin-344

Blocks myostatin, the protein that limits muscle growth.
Can lead to significant size and strength increases but is usually considered more experimental.

4. PEG-MGF (Pegylated Mechano Growth Factor)

A variant of IGF-1 released after muscle damage.
Supports muscle repair and localized growth, often used post-workout.

5. BPC-157 (indirectly)

Not anabolic by itself but excellent for healing tendons, ligaments, and joints.
Supports consistent training, which indirectly improves muscle growth potential.

If the goal is maximum hypertrophy, IGF-1 LR3 is often considered the most effective, but if the goal is safer, steady growth with better recovery, then CJC-1295 + Ipamorelin is a strong option.

1. IGF-1 LR3

Goal: Direct muscle hypertrophy through cell proliferation.
Typical Dose: 20–50 mcg per day, subcutaneously.
Cycle Length: 4–6 weeks. Some protocols use 2–3 weeks on, 1 week off to prevent desensitization.
Timing: Often post-workout for best muscle uptake, but can also be split into morning and post-training doses.
Notes: Extremely potent; watch for side effects like joint pain, water retention, or hypoglycemia.

2. CJC-1295 + Ipamorelin

Goal: Stimulate natural growth hormone release, increase IGF-1.
Typical Dose:
- CJC-1295 (with DAC): 1–2 mg, 1–2x per week.
- CJC-1295 (no DAC) + Ipamorelin: 100 mcg CJC-1295 + 100 mcg Ipamorelin, 1–2x daily.
Cycle Length: 8–12 weeks, sometimes longer since these peptides are mild and have low risk of desensitization.
Timing: Best at night before sleep or pre/post-workout for synergistic GH pulses.
Notes: Gentle on the system; side effects are usually mild (headache, water retention).

3. Follistatin-344

Goal: Myostatin inhibition for increased muscle size potential.
Typical Dose: 50–100 mcg daily, subcutaneously.
Cycle Length: 3–4 weeks, often used in combination with IGF-1 LR3 or GHRH/GHRP peptides.
Notes: Experimental; long-term safety is not well established.

4. PEG-MGF

Goal: Promote localized muscle repair and hypertrophy post-exercise.
Typical Dose: 100–200 mcg, post-workout, subcutaneously.
Cycle Length: 4–6 weeks, often in combination with IGF-1 LR3.
Timing: Immediately after training for best effect.
Notes: Helps recovery and repair; mild systemic effects.

5. BPC-157

Goal: Not anabolic directly, supports recovery from injuries, tendons, ligaments.
Typical Dose: 200–500 mcg daily, subcutaneously at site of injury or systemically.
Cycle Length: 4–8 weeks, often used alongside anabolic peptides to maintain training consistency.
Notes: Very safe, minimal side effects; accelerates recovery and protects joints during heavy training.

Stacking Option for Muscle Growth:

Primary Stack: IGF-1 LR3 + PEG-MGF post-workout.
Support Stack: CJC-1295 + Ipamorelin for overall GH boost.
Recovery Stack: BPC-157 to protect tendons and ligaments.

What is the best peptide to help reduce visceral fat?

When it comes to reducing visceral fat, the peptide with the strongest clinical backing is Tesamorelin.

Here is why it stands out:

Mechanism: Tesamorelin is a synthetic analog of Growth Hormone–Releasing Hormone (GHRH). It stimulates your pituitary gland to release more natural growth hormone, which in turn increases IGF-1. This cascade helps mobilize stored fat, particularly in the visceral (abdominal) area.

Evidence: It has FDA approval for reducing visceral adipose tissue in HIV-associated lipodystrophy, but studies have also shown benefits in non-HIV populations dealing with central obesity.

Results: Clinical trials show reductions in visceral fat while preserving lean muscle mass, which is often a challenge when dieting.

Other benefits: It may improve lipid profiles, insulin sensitivity, and markers of metabolic health, though results vary between individuals.

Other peptides sometimes discussed for fat loss (like CJC-1295/Ipamorelin or AOD-9604) may support overall body composition, but none are as well-documented for specifically targeting visceral fat as Tesamorelin.

Breakdown of Tesamorelin protocols and dosing strategies used for visceral fat reduction, based on clinical and anecdotal sources:

1. Standard Clinical Dose

Dose: 2 mg subcutaneously once daily
Frequency: Every day, usually in the evening
Duration: Typically 3 months to see significant reduction in visceral fat; some protocols extend up to 6 months for continued improvement
Monitoring: Periodic measurement of visceral fat via imaging (CT or MRI) or waist circumference, along with IGF-1 levels to ensure physiological range

2. Administration Tips

Injection site: Rotate subcutaneous sites (abdomen, thighs, upper arm) to minimize irritation
Timing: Evening injections are recommended because natural growth hormone release is higher at night, which may enhance synergy
Lifestyle synergy: Combining Tesamorelin with resistance training and a high-protein, moderate-calorie diet amplifies fat loss while preserving lean mass

3. Expected Results

Clinical trials show 8–15% reduction in visceral fat after 3 months
Subcutaneous fat (the fat under the skin) is less affected
Lean body mass is generally preserved, which is a key advantage over calorie-restricted dieting alone

4. Safety Considerations

Generally well-tolerated, but possible side effects include:
Mild injection site reactions
Joint stiffness or swelling
Temporary glucose intolerance in some cases
People with active cancer, pituitary disorders, or uncontrolled diabetes should avoid it unless supervised by a physician

5. Alternatives / Adjuncts

CJC-1295 + Ipamorelin: May improve growth hormone pulpability and support lean mass, but visceral fat reduction is less pronounced than Tesamorelin
AOD-9604: Mild lipolytic effect; mostly subcutaneous fat, minimal visceral impact

CJC-1295 and CJC-1295 with DAC

CJC-1295 Overview

Type: Synthetic peptide, growth hormone-releasing hormone (GHRH) analog

Purpose: Stimulates the pituitary gland to release growth hormone (GH), which can support muscle growth, fat loss, recovery, and anti-aging effects.

Mechanism of Action CJC-1295 binds to GHRH receptors in the pituitary, signaling the gland to release more GH. This also indirectly increases IGF-1 (insulin-like growth factor-1) levels, which mediates many of GH’s anabolic effects.

Half-Life: 30 minutes – this is relatively short, which means it requires multiple injections per day to maintain stable GH release if not modified.

Administration: Subcutaneous injections (typically in the abdomen or thigh). Dosing protocols vary, but daily or multiple times per week injections are common.

Benefits: Supports lean muscle growth, helps reduce body fat, especially visceral fat, may improve sleep quality and recovery. Anti-aging potential via improved skin elasticity and tissue repair. Can support bone density and joint health

Drawbacks: Short half-life means frequent injections.

Potential side effects: water retention, tingling or numbness, headache, or mild fatigue.

CJC-1295 with DAC (Drug Affinity Complex) Type: Modified version of CJC-1295.

Purpose: Designed for longer-lasting GH release, reducing the need for frequent injections.

Mechanism of Action: The DAC modification allows CJC-1295 to bind to albumin in the blood, significantly prolonging its half-life. This allows for sustained GH and IGF-1 release over 6–8 days from a single injection.

Half-Life: 6–8 days (much longer than standard CJC-1295)

Administration: Subcutaneous injections; usually once or twice per week is sufficient due to the extended half-life.

Benefits: All benefits of standard CJC-1295, but more convenient dosing sustained GH and IGF-1 levels without daily injections. Potentially more stable and consistent anabolic and anti-aging effects.

Drawbacks: Because GH levels are elevated for longer periods, there may be higher risk of side effects in sensitive individuals. Less flexible for “pulse” GH therapy approaches.

Prolonged exposure; slightly higher risk if sensitive in short, CJC-1295 is better if you want more precise GH pulses and are okay with daily injections. CJC-1295 with DAC is more convenient, maintaining GH and IGF-1 levels for days with fewer injections. Both share similar benefits for muscle growth, fat reduction, and anti-aging, but dosing strategy and monitoring GH levels are key to safety.

CJC-1295 (without DAC)

Typical dose: 100–200 mcg per injection.

Frequency: 1–3 times per day (often morning and before bed to mimic natural GH pulses)

Administration: Subcutaneous injection, usually in the abdomen or thigh

Cycle length: 4–12 weeks is common, followed by a break to avoid desensitization.

Notes: Because of the short half-life (30 min), multiple daily injections give the most consistent GH pulses. Some users split doses for morning and pre-sleep to optimize fat loss and recovery.

CJC-1295 with DAC

Typical dose: 1–2 mg per week. If your a beginner you should start with 500mcgs to see how your body responds.

Frequency: 1–2 injections per week due to the long half-life (6–8 days)

Administration: Subcutaneous injection

Cycle length: 4–12 weeks is common; some users go longer with monitoring

Notes: The sustained GH release reduces the need for daily dosing. Because GH levels remain elevated for days, some prefer to start at lower doses to assess tolerance.

Additional Practical Tips:

1. Injection sites- Rotate injection sites (abdomen, thigh) to avoid tissue irritation.

2. Timing-For non-DAC CJC-1295, morning and bedtime injections mimic natural GH rhythm; DAC form timing is flexible due to sustained release.

3. Stacking-Often paired with peptides like Ipamorelin for synergistic GH stimulation.

4. Monitoring- Periodic IGF-1 or GH blood tests help ensure dosing is effective but safe.

5. Side effects to watch- Water retention, tingling, headaches, or joint pain. Adjust dose if these appear.

GLP-1 and GLP-2 receptor agonist

1. Semaglutide:

Class: GLP-1 receptor agonist
Mechanism: Mimics the action of glucagon-like peptide-1 (GLP-1), a hormone released after meals that enhances insulin secretion, slows gastric emptying, reduces glucagon release, and increases satiety.

Uses:

Originally developed for type 2 diabetes (brands: Ozempic, Rybelsus for oral version).
Widely used for weight management (brand: Wegovy).

Administration:

Injectable (once-weekly subcutaneous) or oral (daily tablets, though less bioavailable).

Benefits:

Significant weight reduction, often greater than older GLP-1 agonists.
Strong glucose-lowering effect, improves HbA1c.
May reduce cardiovascular risk in type 2 diabetes.

Limitations/Side Effects:

Nausea, vomiting, constipation, or diarrhea are common.
Risk of pancreatitis and gallbladder disease is debated.
Contraindicated in individuals with a history of medullary thyroid carcinoma or MEN2 (in animals, thyroid C-cell tumors were observed).

2. Liraglutide:

Class: GLP-1 receptor agonist (earlier generation than semaglutide).
Mechanism: Same as semaglutide, but shorter half-life. Requires daily dosing.
Uses:
Type 2 diabetes (brand: Victoza).
Weight management (brand: Saxenda).

Administration:

Once-daily subcutaneous injection.

Benefits:
Improves blood sugar control.
Promotes weight loss, though typically less than semaglutide.
Proven cardiovascular benefits in type 2 diabetes (reduced risk of heart attack, stroke, and death).

Limitations/Side Effects:

Gastrointestinal issues similar to semaglutide.
Daily injection is less convenient.
Same thyroid and pancreatitis precautions.

3. Tirzepatide:

Class: Dual GLP-1 and GIP receptor agonist (called a "twincretin").

Mechanism:
Activates GLP-1 receptors like semaglutide and liraglutide.
Also activates GIP (glucose-dependent insulinotropic polypeptide) receptors, which may further enhance insulin secretion and fat metabolism.

Uses:

Approved for type 2 diabetes (brand: Mounjaro).
Recently approved for weight loss (brand: Zepbound).

Administration:

Once-weekly subcutaneous injection.

Benefits:

Typically produces even greater weight loss than semaglutide, with some patients losing 20% or more of body weight.
Very effective at lowering blood glucose and HbA1c.

Limitations/Side Effects:

Same gastrointestinal issues as GLP-1 drugs, sometimes stronger.
Long-term data on cardiovascular protection is still being gathered, though early signs are positive.
Same thyroid/pancreatitis cautions.

In simple terms:

Liraglutide works well but needs daily shots and is less powerful.
Semaglutide is stronger, more convenient (weekly), and widely used for weight loss and diabetes.
Tirzepatide is the newest and seems to outperform both, but long-term safety and outcomes are still being studied.

1. Liraglutide (Saxenda, Victoza):

Starting dose: 0.6 mg once daily (subcutaneous).
Titration: Increase by 0.6 mg each week until the target is reached.
Weight management target dose: 3.0 mg daily (Saxenda).
Diabetes target dose: 1.2–1.8 mg daily (Victoza).

Notes:

Daily injection is required due to its shorter half-life.
Some patients can’t tolerate 3.0 mg and stay on lower doses.

2. Semaglutide (Ozempic, Wegovy, Rybelsus):

Injectable (Ozempic/Wegovy)
Start: 0.25 mg once weekly.
Increase: 0.25 mg every 4 weeks

Usual doses:

-Diabetes (Ozempic): 0.5–1.0 mg weekly (up to 2 mg).

-Weight loss (Wegovy): 2.4 mg weekly is the target dose.

Oral (Rybelsus):

-Start: 3 mg daily for 30 days.

-Increase: 7 mg daily, then up to 14 mg if needed.

Notes:

-Longer half-life allows once-weekly dosing.

-Wegovy dosing escalates more slowly to help with tolerability.

3. Tirzepatide (Mounjaro, Zepbound)

Starting dose: 2.5 mg once weekly.

Titration: Increase by 2.5 mg every 4 weeks.

Usual target doses:

-5 mg, 10 mg, or 15 mg weekly, depending on tolerance and goals.

Notes:

-Even at the lowest doses, patients often see significant effects.

-Higher doses (10–15 mg) drive the most weight loss but also more GI side effects.

How doctors typically approach it:

Start low and slow to avoid nausea and vomiting.
Stay on a tolerable dose if side effects appear, then try increasing later.
If someone cannot tolerate a GLP-1 at all, they may stay at the lowest effective dose rather than hitting the “maximum” target.

Best for Fat Loss:

Tirzepatide (Mounjaro/Zepbound)
Head-to-head trials show it outperforms semaglutide for weight loss.
Average reductions: ~15–20% body weight at higher doses, some patients exceeding that.
Works by combining GLP-1 + GIP agonism, which seems to boost both appetite suppression and fat metabolism.
Semaglutide is also excellent, producing ~10–15% average weight loss, but usually less than tirzepatide.
Liraglutide lags behind, with average weight loss of ~5–8%, and requires daily injections.

Ranking for fat loss:

Tirzepatide
Semaglutide
Liraglutide

Best for Blood Sugar Control (Type 2 Diabetes):

Tirzepatide shows the largest reductions in HbA1c, often 2% or more, which is very strong.
Semaglutide comes next, usually lowering HbA1c by 1–1.5%.
Liraglutide is effective but tends to be the least potent of the three, around 0.8–1.2% HbA1c reduction.

Ranking for glucose control:

Tirzepatide
Semaglutide
Liraglutide

Best for Cardiovascular Protection:

Liraglutide and semaglutide both have long-term trial data showing reduced risk of heart attack, stroke, and cardiovascular death in high-risk type 2 diabetics.
Tirzepatide looks promising, but large cardiovascular outcome trials are still ongoing, so it doesn’t yet have the same level of proof.

Ranking for heart protection (so far):

Liraglutide / Semaglutide (tie, proven)
Tirzepatide (likely good, but still under study)

Overall Takeaway:

If fat loss is the primary goal: Tirzepatide is the strongest option.
If diabetes control is the primary goal: Tirzepatide still leads, but semaglutide is a close second and already well-established.
If cardiovascular risk reduction is the top concern: Semaglutide or liraglutide are safer bets until more tirzepatide data comes in.

1. Liraglutide (Saxenda for weight, Victoza for diabetes):

Starting dose: 0.6 mg subcutaneous daily
Titration: Increase by 0.6 mg each week

Target dose:

-Weight loss (Saxenda): 3.0 mg daily

-Diabetes (Victoza): 1.2–1.8 mg daily

Notes:

-Daily injection required due to short half-life

-If side effects are severe, remain on the current dose until tolerated

2. Semaglutide (Ozempic/Wegovy injectable, Rybelsus oral)

Injectable (weekly) – Ozempic/Wegovy

Start: 0.25 mg weekly
Titration: Increase every 4 weeks
Target dose:

-Diabetes (Ozempic): 0.5–1 mg weekly, can increase to 2 mg if needed

-Weight loss (Wegovy): 2.4 mg weekly

Notes: Once-weekly injection improves convenience and compliance

Oral (Rybelsus)

Start: 3 mg daily for 30 days
Titration: Increase to 7 mg daily, then 14 mg if needed
Notes: Absorption is lower than injectable; must take on empty stomach

3. Tirzepatide (Mounjaro, Zepbound)

Start dose: 2.5 mg weekly
Titration: Increase by 2.5 mg every 4 weeks
Target dose: 10–15 mg weekly depending on goals and tolerance

Notes:

Weekly injection
Higher doses give stronger weight loss but also higher risk of GI side effects

Practical Tips for Dosing

Start low, go slow – all three drugs can cause nausea, vomiting, and diarrhea if titrated too quickly.
Monitor tolerance – stay at a dose until side effects are manageable before increasing.
Consistency matters – weekly injections should be given on the same day each week; daily injections at roughly the same time each day.
Adjustments for renal/hepatic issues – dosing may need modification; always follow a physician’s guidance.

Key Notes

Liraglutide: daily injection; titrate weekly by 0.6 mg until 3.0 mg. Stop at lower dose if side effects persist.
Semaglutide: weekly injection; start low to prevent nausea, gradually increase to target (2.4 mg for weight loss). Oral form is slower to titrate.
Tirzepatide: weekly injection; increase by 2.5 mg every 4 weeks until goal dose (usually 10–15 mg). GI side effects often peak during titration.

NAD+ oral and injectable information

NAD+ (Nicotinamide Adenine Dinucleotide) is a coenzyme found in all living cells. It plays a central role in energy metabolism, DNA repair, gene expression, and cellular signaling. As we age, NAD+ levels naturally decline, which is linked to reduced mitochondrial efficiency, slower metabolism, and increased susceptibility to age-related disease. Because of this, NAD+ supplementation has gained a lot of attention in the anti-aging and biohacking space.

Oral NAD+ Supplements:

Oral delivery typically comes in the form of NAD+ precursors rather than pure NAD+ itself, since NAD+ is not well absorbed in the digestive tract. The most common precursors are nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN).

Mechanism:

These compounds enter the bloodstream after digestion.
Once inside cells, they undergo conversion through enzymatic pathways into NAD+.

Pros:

Convenient (pills, powders, sublingual lozenges).
Relatively inexpensive compared to injections or IV infusions.
Can be used daily for long-term maintenance.

Cons:

Lower bioavailability compared to injectable NAD+.
Requires the body to convert precursors into NAD+, and efficiency can vary between individuals.
Effects tend to be more gradual and subtle.

Typical Use:

NR: 250–500 mg daily.
NMN: 250–1000 mg daily.

These doses are often stacked with lifestyle strategies like fasting, exercise, and sirtuin activators (resveratrol, pterostilbene) for synergistic effects.

Injectable NAD+:

Injectable NAD+ is usually administered either intramuscularly (IM) or intravenously (IV). Unlike oral precursors, injectable NAD+ delivers the coenzyme directly into circulation in its active form.

Mechanism:

Bypasses digestion and conversion steps.
Provides a rapid rise in systemic NAD+ levels.
Readily taken up by cells to support mitochondrial function and repair.

Pros:

Much higher bioavailability and faster onset than oral routes.
Can provide immediate effects in energy, cognition, and recovery.
Used in clinical settings for addiction recovery, chronic fatigue, depression, and neurodegenerative conditions.

Cons:

Requires professional administration (especially IV).
Can be uncomfortable: NAD+ infusions often cause chest tightness, flushing, or nausea if pushed too fast.
Expensive compared to oral options.
Not as practical for daily use.

Typical Use:

IV NAD+ protocols: 250–1000 mg per infusion, often given over 2–4 hours.
IM injections: smaller doses, 50–200 mg, for quicker but less intense boosts.
Often used in cycles, like a few infusions over 5–10 days, then maintenance sessions every few weeks or months.

Practical Takeaway

Oral precursors (NMN/NR) are best for long-term, consistent maintenance of NAD+ levels and general anti-aging purposes.
Injectable NAD+ is better suited for people looking for rapid results, recovery from burnout, addiction, or neurological support, but it’s less practical for everyday use

1. Oral NAD+ (NR or NMN)

Since oral NAD+ itself isn’t well absorbed, people use precursors like NR or NMN:

Typical dosing: Daily Dose

Nicotinamide Riboside (NR)

250–500 mg

Usually split into 1–2 doses; taken with or without food. Higher doses (up to 1000 mg) are sometimes used in research.

Nicotinamide Mononucleotide (NMN)

Dose: 250–1000 mg

Often split into morning and afternoon doses to avoid sleep disturbance, since NAD+ can slightly increase energy.

Tips:

Take in the morning if you want energy or cognitive benefits.
Can be stacked with resveratrol, pterostilbene, or alpha-lipoic acid for synergistic NAD+ support.
Effects are gradual; consistent daily use is key.

2. Injectable NAD+ (IV or IM)

Intravenous (IV) NAD+:

Dose: 250–1000 mg per session (sometimes up to 1500–2000 mg for intensive therapy).
Frequency: Often administered over 2–4 hours per infusion.
Protocol: Commonly 5–10 sessions in a row for intensive therapy, then maintenance infusions every 1–3 months.
Notes: Infusion speed matters—too fast can cause nausea, flushing, or anxiety. Administering over 2–4 hours is standard.

Intramuscular (IM) NAD+:

Dose: 50–200 mg per injection.
Frequency: Can be given a few times per week depending on goals.
Notes: IM dosing is less intense than IV but still more direct than oral supplementation.

3. Safety Considerations

Oral NR/NMN is generally well-tolerated with minimal side effects (mild nausea or digestive discomfort possible).
IV NAD+ can cause flushing, sweating, mild anxiety, or chest tightness if infused too quickly.
Always work with a qualified clinician for injectable NAD+, especially at higher doses.

Oral – Nicotinamide Riboside (NR) 250–500 mg (up to 1000 mg) Daily

Continuous, long-term

General anti-aging, energy support, cognitive enhancement. Split into 1–2 doses. Take in morning for energy.

Oral – Nicotinamide Mononucleotide (NMN) 250–1000 mg. Daily Continuous, long-term Supports NAD+ levels, mitochondrial function, metabolic health. Morning/afternoon dosing preferred.

IV NAD+

250–1000 mg (up to 2000 mg in intensive therapy)

1–10 sessions initially; maintenance every 1–3 months

Infused over 2–4 hours

Rapid energy boost, neuroprotection, recovery, addiction therapy, chronic fatigue. Administer slowly to avoid side effects.

IM NAD+

50–200 mg 2–3 times per week depending on goal.

Short-term or maintenance cycles:

Moderate boost in energy, cellular repair support. Less intense than IV but more direct than oral.

Practical Guidelines:

Consistency matters: Oral NAD+ works best with daily use over weeks to months.
Infusion speed is critical: For IV NAD+, slower is safer—never rush the dose.
Stacking: Oral NAD+ often works best with supporting compounds like resveratrol or pterostilbene.
Cycle vs Maintenance:
- Oral: continuous daily dosing is fine.
- IV: intensive cycle first, then maintenance every few months.
- IM: can be used as mini-maintenance in between IV sessions.

Disclaimer

The information provided above is not intended to substitute medical advice, diagnosis, or treatment. Should you have any questions regarding a medical condition, seek the advice of your physician or a qualified healthcare provider. In no case should medical advice be disregarded or delayed because of what you have read or seen.

Delta Sleep-Inducing Peptide (DSIP)

Sermorelin

MOTS-C

Semax and Selank

GHK-Cu

​

​

NAD+ oral and injectable information

Disclaimer